Document and Entity Information Entity Addresses [Table] Entity Addresses [Line Items] Document Type Document Quarterly Report Document Period End Date Document Transition Report Entity File Number Entity Registrant Name Entity Incorporation, State or Country Code Entity Tax Identification Number Entity Address, Address Line One Entity Address, City or Town Entity Address, State or Province Entity Address, Postal Zip Code City Area Code Local Phone Number Title of 12(b) Security Trading Symbol Security Exchange Name Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Entity Shell Company Entity Shell Company Entity Common Stock, Shares Outstanding Entity Central Index Key Current Fiscal Year End Date Document Fiscal Year Focus Document Fiscal Period Focus Amendment Flag CONDENSED CONSOLIDATED BALANCE SHEETS Assets [Abstract] ASSETS Assets, Current [Abstract] Current assets: Cash and Cash Equivalents, at Carrying Value Cash and cash equivalents Cash and cash equivalents Restricted Cash, Current Restricted cash Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and deposits that are expected to be realized or consumed within one year or the normal operating cycle, if longer. Prepaid Expense And Deposits, Current Prepaid expenses and deposits Other Receivables, Net, Current Other receivables Assets, Current Total current assets Assets Total assets Liabilities and Equity [Abstract] LIABILITIES AND STOCKHOLDERS' EQUITY Liabilities, Current [Abstract] Current liabilities: Accounts Payable and Accrued Liabilities, Current Accounts payable and accrued liabilities Due to Related Parties, Current Related party payable Other Liability, Current, Related Party, Type [Extensible Enumeration] Deferred Revenue, Current Deferred revenue Liabilities, Current Total current liabilities Liabilities Total liabilities Stockholders' Equity Attributable to Parent [Abstract] Stockholders' equity: Preferred Stock, Value, Issued Preferred stock, $0.001 par value, 5 million shares authorized, 0 shares issued and outstanding at June 30, 2025 and December 31, 2024 , respectively Common Stock, Value, Issued Common stock, $0.001 par value, 30 million shares authorized, 11.3 million and 10.7 million shares issued and outstanding as of June 30, 2025 and December 31, 2024, respectively (see Note 8) Additional Paid in Capital Additional paid-in capital Retained Earnings (Accumulated Deficit) Accumulated deficit Stockholders' Equity Attributable to Parent Ending Balance Beginning Balance Total stockholders' equity Liabilities and Equity Total liabilities and stockholders' equity Statement [Table] Statements Statement Preferred Stock, Par or Stated Value Per Share Preferred stock par value (in $ per share) Preferred Stock, Shares Authorized Preferred stock authorized (in shares) Preferred Stock, Shares Issued Preferred stock issued (in shares) Preferred Stock, Shares Outstanding Preferred stock outstanding (in shares) Common Stock, Par or Stated Value Per Share Common stock par value (in $ per share) Common Stock, Shares Authorized Common stock authorized (in shares) Common Stock, Shares, Issued Common stock issued (in shares) Common Stock, Shares, Outstanding Common stock outstanding (in shares) CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS Product and Service [Axis] Product and Service [Domain] Grant [Member] Grant income Revenues [Abstract] Revenues: Revenue from Contract with Customer, Including Assessed Tax Revenue recognized Total revenues Costs and Expenses [Abstract] Operating expenses: Research and Development Expense Research and development General and Administrative Expense General and administrative The amount of gain (loss) on early termination of vendor agreement. Gain (Loss) on Early Termination of Vendor Agreement Loss on early termination of vendor agreement Gain (loss) on early termination of vendor agreement Operating Expenses Total operating expenses Operating Income (Loss) Loss from operations Nonoperating Income (Expense) [Abstract] Other income (expenses): Investment Income, Interest Interest income Other Nonoperating Income Other income Net loss Net loss Earnings Per Share [Abstract] Net loss per share: Earnings Per Share, Basic Net loss per share, basic (in dollars per share) Loss from per share, basic (in dollars per share) Earnings Per Share, Diluted Net loss per share, diluted (in dollars per share) Loss from per share, diluted (in dollars per share) Earnings Per Share, Basic, Other Disclosure [Abstract] Weighted average number of common shares outstanding: Weighted Average Number of Shares Outstanding, Basic Weighted average number of common shares outstanding, basic (in shares) Weighted average common shares outstanding, basic Weighted Average Number of Shares Outstanding, Diluted Weighted average number of common shares outstanding, diluted (in shares) Weighted average common shares outstanding, diluted CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY Equity Components [Axis] Equity Component [Domain] Common Stock [Member] Common Stock Additional Paid-in Capital [Member] Additional Paid-in Capital Retained Earnings [Member] Accumulated Deficit Shares, Issued Ending Balance, Shares Beginning Balance, Shares Value of stock issued as a result of the exercise of warrants. Stock Issued During Period, Value, Warrants Exercised Issuance of common stock from exercise of prefunded warrants Number of warrants exercised during the period. Stock Issued During Period, Shares, Warrants Exercised Issuance of common stock from exercise of prefunded warrants (in shares) Stock Issued During Period, Value, New Issues Shares purchased pursuant to ATM agreement Stock Issued During Period, Shares, New Issues Shares purchased pursuant to ATM agreement (in shares) Number of shares issued (in shares) Stock Issued During Period, Value, Stock Options Exercised Issuance of common stock from exercise of stock options Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period Issuance of common stock from exercise of stock options (in shares) Issuance of common stock from exercise of stock options (in shares) Shares Issued, Value, Share-Based Payment Arrangement, after Forfeiture Stock-based compensation CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS Net Cash Provided by (Used in) Operating Activities [Abstract] Cash Flows from Operating Activities: Net Income (Loss), Including Portion Attributable to Noncontrolling Interest Net loss Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract] Reconciliation of net loss to net cash used in operating activities: Share-Based Payment Arrangement, Noncash Expense Stock-based compensation Increase (Decrease) in Operating Capital [Abstract] Changes in operating assets and liabilities: Amount of increase (decrease) in prepaid expenses and deposits. Increase (Decrease) In Prepaid Expense And Deposits Prepaid expenses and deposits Increase (Decrease) in Accrued Interest Receivable, Net Other receivables Increase (Decrease) in Due to Related Parties, Current Related party payable Increase (Decrease) in Accounts Payable and Accrued Liabilities Accounts payable and accrued expenses Increase (Decrease) in Deferred Revenue Deferred revenue Net Cash Provided by (Used in) Operating Activities Net cash used in operating activities Net Cash Provided by (Used in) Financing Activities [Abstract] Cash Flows from Financing Activities: Proceeds from Issuance of Common Stock Proceeds from issuance of common stock, net Amount of cash inflow from exercise of options and warrants. Proceeds from Warrants and Stock Options Exercised Proceeds from exercise of warrants and stock options Net Cash Provided by (Used in) Financing Activities Net cash provided by financing activities Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect Net (decrease) increase in cash, cash equivalents, and restricted cash Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents Cash, cash equivalents, and restricted cash at end of the period Cash, cash equivalents, and restricted cash at beginning of the period Total cash, cash equivalents and restricted cash NATURE OF OPERATIONS Nature of Operations [Text Block] NATURE OF OPERATIONS n/a BASIS OF PRESENTATION Basis of Accounting [Text Block] BASIS OF PRESENTATION n/a LIQUIDITY AND FINANCIAL CONDITION Liquidity Financial Condition And Going Concern Text Block Liquidity Financial Condition And Going Concern [Text Block] LIQUIDITY AND FINANCIAL CONDITION SIGNIFICANT ACCOUNTING POLICIES Significant Accounting Policies [Text Block] SIGNIFICANT ACCOUNTING POLICIES NET LOSS PER SHARE Noncontrolling Interest Disclosure [Text Block] NET LOSS PER SHARE OTHER RECEIVABLE Loans, Notes, Trade and Other Receivables Disclosure [Text Block] OTHER RECEIVABLE ACCOUNTS PAYABLE, ACCRUED LIABILITIES AND RELATED PARTY PAYABLE Accounts Payable and Accrued Liabilities Disclosure [Text Block] ACCOUNTS PAYABLE, ACCRUED LIABILITIES AND RELATED PARTY PAYABLE STOCKHOLDERS' EQUITY Stockholders' Equity Note Disclosure [Text Block] STOCKHOLDERS' EQUITY STOCK-BASED COMPENSATION Disclosure of Compensation Related Costs, Share-based Payments [Text Block] STOCK-BASED COMPENSATION GRANT INCOME Revenue from Contract with Customer [Text Block] GRANT INCOME COMMITMENTS AND CONTINGENCIES Commitments and Contingencies Disclosure [Text Block] COMMITMENTS AND CONTINGENCIES RELATED PARTY EXPENSES Related Party Transactions Disclosure [Text Block] RELATED PARTY EXPENSES SUBSEQUENT EVENTS Subsequent Events [Text Block] SUBSEQUENT EVENTS Consolidation, Policy [Policy Text Block] Principles of Consolidation Use of Estimates, Policy [Policy Text Block] Use of Estimates Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block] Cash, Cash Equivalents, Restricted Cash, and Credit Risk Compensation Related Costs, Policy [Policy Text Block] Modification of Stock Options Segment Reporting, Policy [Policy Text Block] Segment Reporting Disclosure of accounting policy for recently issued accounting standards not yet adopted. Recently Issued Accounting Standards Not yet Adopted [Policy Text Block] Recently Issued Accounting Standards Not Yet Adopted Schedule of Earnings Per Share, Basic and Diluted [Table Text Block] Schedule of computation of net loss per share Tabular disclosure of net loss per share. Net Loss Per Share [Table Text Block] Schedule of anti-dilutive securities Schedule of Accounts Payable and Accrued Liabilities [Table Text Block] Schedule of accounts payable, accrued liabilities, and related party payable Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block] Summary of warrants outstanding Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table] Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] STOCK-BASED COMPENSATION Share-based Payment Arrangement, Activity [Table Text Block] Schedule of the company's stock option activity Schedule or Description of Weighted Average Discount Rate [Table Text Block] Schedule of weighted average assumptions used in calculating the fair values of stock options that were granted Tabular disclosure of stock based compensation expenses recorded. Stock based Compensation Expenses [Table Text Block] Schedule of stock-based compensation expenses Schedule of Related Party Transactions [Table Text Block] Schedule of related party transaction expenses Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed. Financial Condition Going Concern And Management Plans [Table] This member represents information pertaining to National Institutes of Health Small Business Innovation Research. National Institutes of Health Small Business Innovation Research [Member] SBIR AML SBIR grant Represents information pertaining to grants from National Institutes of Health-National Cancer Institute. National Institutes of Health National Cancer Institute Grant [Member] National Institutes of Health National - Cancer Institute Grant Represents information pertaining to grant from National Institutes of Health and Business Innovation research for Lymphoma. National Institutes of Health Small Business Innovation Research For Lymphoma Grant [Member] SBIR lymphoma grant Represents information pertaining to grant from National Institutes of Health and Business Innovation research for pancreatic cancer. National Institutes of Health Small Business Innovation Research For Pancreatic Cancer [Member] SBIR pancreatic cancer grant Award of money not required to be repaid for FDA grant. FDA Grant [Member] FDA grant Award of money not required to be repaid for additional CPRIT grant. Additional CPRIT Grant [Member] Additional CPRIT grant Sale of Stock [Axis] Sale of Stock [Domain] Private Placement [Member] Private Placement Represents information pertaining to At The Market Offering. At The Market Offering [Member] Market Offering Class of Warrant or Right [Axis] Class of Warrant or Right [Domain] Represents information pertaining to pre-funded warrants. Pre Funded Warrant [Member] Pre Funded Warrant Pre-funded warrants Represents information pertaining to private placement warrants. Private Placement Warrant [Member] Private Placement Warrant Private placement warrants Subsequent Event Type [Axis] Subsequent Event Type [Domain] Subsequent Event [Member] Subsequent event Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. FINANCIAL CONDITION, GOING CONCERN AND MANAGEMENT PLANS [Line Items] FINANCIAL CONDITION, GOING CONCERN AND MANAGEMENT PLANS Represents the percent of calculation of compensation rate by using gross sales price per share sold. Common Stock, Shares, Commission Rate Calculation on Gross Sales Price per Share, Percent Commission rate Sale of Stock, Consideration Received on Transaction Net proceeds from the sale of securities Shares Issued, Price Per Share Purchase price Average price per share Research and Development Arrangement, Contract to Perform for Others, Compensation Earned Amount of notice received Funds received from grant. Funds Received From CPRIT Grant Funds received from CPRIT grant Revenue from grant related to CPRIT. Revenue From Grant Related to CPRIT Revenue from CPRIT Amount of receivable from Orphan Products Grant program. Orphan Products Grant Program Grant income receivable Amount of grant income transfer product and service to customer for which consideration has been received or is receivable. Grant Received Grant income received Funds received from grant Funds Received From Grant Funds received from grant Grants Receivable Grant receivable Duration of grant assistance transaction, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Grant Assistance Term Grant Assistance Term Class of Warrant or Right, Number of Securities Called by Warrants or Rights Issuance of shares of common stock The amount of cash held at financial institutions. Cash at Financial Institutions Cash at financial institutions US Government Agencies Securities, at Carrying Value Government agency securities Share-Based Payment Arrangement, Plan Modification, Incremental Cost Incremental stock-based compensation expense in connection with the termination of certain employees Stock-based compensation expense Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table] Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] NET LOSS PER SHARE Net Income (Loss) Attributable to Parent, Diluted [Abstract] Numerator: Weighted Average Number of Shares Outstanding, Diluted [Abstract] Denominator: Antidilutive Securities [Axis] Antidilutive Securities, Name [Domain] Employee Stock Option Warrant [Member] Common stock purchase warrants Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount Potentially dilutive securities Schedule of Receivables with Imputed Interest [Table] Government Assistance, Type [Axis] Government Assistance, Type [Domain] Represents information pertaining to Cancer Prevention And Research Institute Of Texas grant for Acute Myeloid Leukemia. Cancer Prevention And Research Institute Of Texas, Acute Myeloid Leukemia [Member] CPRIT AML Receivables with Imputed Interest [Line Items] OTHER RECEIVABLE Grants Receivable, Current Grants receivable - Current This table lists the accounts payable and accrued liabilities. The line items identify information about the accounts payable and accrued liabilities. Accounts Payable And Accrued Liabilities [Table] Related Party [Axis] Related Party [Domain] Related Party [Member] Related party Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. Accounts Payable And Accrued Liabilities [Line Items] ACCOUNTS PAYABLE, ACCRUED LIABILITIES AND RELATED PARTY PAYABLE Accounts Payable, Current Accounts payable Employee-related Liabilities, Current Compensation and benefits Accrued Professional Fees, Current Professional fees The amount of tax fees payable. Tax Fees Payable Tax fees Other Accrued Liabilities, Current Other Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits. Accounts Payable and Accrued Liabilities Including Related party payable, Current Total accounts payable, accrued liabilities and related party payable Subsidiary or Equity Method Investee, Sale of Stock by Subsidiary or Equity Investee [Table] Subsidiary, Sale of Stock [Line Items] STOCKHOLDERS' EQUITY Class of Warrant or Right [Table] Class of Warrant or Right [Line Items] STOCKHOLDERS' EQUITY Class of Warrant or Right, Exercise Price of Warrants or Rights Exercise Price Per Share Warrants and Rights Outstanding, Maturity Date Warrants Expiration Date Class of Warrant or Right, Outstanding Outstanding at the end Outstanding at the beginning Number of warrants or rights exercised by the holders of the instruments during the reporting period. Class of Warrant or Right, Exercised Exercised Option Indexed to Issuer's Equity, Type [Axis] Option Indexed to Issuer's Equity, Type [Domain] Plan Name [Axis] Plan Name [Domain] Represents member information pertaining to 2020 equity incentive plan. Equity Incentive Plan 2020 [Member] 2020 Equity Incentive Plan Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number Number of Shares Outstanding, Ending Balance Number of Shares Outstanding, Beginning Balance Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross Number of Shares, Granted Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period Number of Shares, Cancelled / Expired Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number Number of Shares, Options vested and exercisable Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price Weighted Average Exercise Price per Share, Outstanding, Ending Balance Weighted Average Exercise Price per Share, Outstanding, Beginning Balance Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price Exercise price of options granted Weighted Average Exercise Price per Share, Granted Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price Weighted Average Exercise Price per Share, Cancelled / Expired Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price Weighted Average Exercise Price, Options vested and exercisable Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value Total Intrinsic Value Outstanding Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value Total Intrinsic Value, Options vested and exercisable Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term Weighted Average Remaining Contractual Life, Outstanding (in years) Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Remaining Contractual Term Weighted Average Remaining Contractual Life, Options vested and exercisable (in years) Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Exercise Price Exercise price Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term Expected term (years) Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate Expected stock price volatility Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate Risk-free rate of interest Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate Expected dividend rate Income Statement Location [Axis] Income Statement Location [Domain] Research and Development [Member] Research and development General and Administrative [Member] General and administrative Allocated Share-based Compensation Expense Total stock compensation expenses Represents information pertaining to 2025 equity incentive awards. Equity Incentive Award 2025 [Member] 2025 Equity Incentive Awards Grantee Status [Axis] Grantee Status [Domain] Employees [Member] Employees Non-Employee [Member] Non employee Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized Number of options to purchase shares Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount Total stock-based compensation cost related to unvested awards not yet recognized Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition Expected weighted average period of recognition of unrecognized compensation costs (in years) This table lists the grant income. Grant Income [Table] Award of money not required to be repaid for CPRIT grant. CPRIT Grant [Member] CPRIT grant Represents information pertaining to Cancer Prevention and Research Institute of Texas grant for metastatic pancreatic cancer. Cancer Prevention And Research Institute Of Texas, Metastatic Pancreatic Cancer [Member] CPRIT Pancreatic Line items represents grant income. Grant Income [Line Items] GRANT INCOME Receipt of product development research award Receipt Of Product Development Research Award Receipt of product development research award Commitments And Contingencies [Table] Related Party Transaction [Axis] Related Party Transaction [Domain] Represents information pertaining to the grant agreement with Cancer Prevention and Research Institute Of Texas ("CPRIT"). Cancer Prevention And Research Institute Of Texas Grant Agreement [Member] Cancer Prevention and Research Institute of Texas Represents information pertaining to the exclusive license agreement with Baylor College of Medicine ("BCM"). Baylor College Of Medicine License Agreement [Member] License agreement with Baylor College of Medicine Commitments And Contingencies [Line Items] COMMITMENTS AND CONTINGENCIES The percentage of net sales of any product to the grants received by the entity for which payments have to be made as per the terms of the grant agreement. Grant Agreement, Payments Required, Percentage Of Net Sales To Grants Received Aggregate amount (in Percentage) The percentage of revenue sharing by the entity with the counter party for the remainder revenue term as per the terms of the grant agreement. Grant Agreement, Revenue Sharing Percentage, Remainder of Revenue Term Revenue sharing percentage The value of shares issued or sold by the entity for the stock transaction during the reporting period. Sale of Stock, Value of Shares Issued in Transaction Shares issued in common stock value The aggregate amount of the milestone payments agreed to be paid by the entity as per the terms of the license agreement. License Agreement, Maximum Milestone Payments Agreed To Be Paid Milestone payments agreed The percentage of the liquidity event proceeds that will be paid as a one-time liquidity incentive payment by the entity as per the terms of the license agreement. License Agreement, Liquidity Incentive Payment Percentage Liquidity incentive payment in percentage Schedule of Related Party Transactions, by Related Party [Table] Counterparty Name [Axis] Counterparty Name [Domain] Represents the information pertaining to Cell Ready. Cell Ready [Member] Cell Ready Represents information pertaining to Clinical Trial Agreement with Baylor College of Medicine. Clinical Trial Agreement with Baylor College of Medicine [Member] Baylor College of Medicine Represents the information pertaining to Cell Ready Agreement. Cell Ready Agreement [Member] Cell Ready Represents information pertaining to Clinical Trial Agreement with Wilson Wolf Manufacturing Corporation. Wilson Wolf Manufacturing Corporation [Member] Wilson Wolf Manufacturing Corporation Represents of baylor college of medicine. Baylor College of Medicine [Member] BCM Related Party Transaction [Line Items] RELATED PARTY EXPENSES Related Party Transaction, Expenses from Transactions with Related Party Total related party expenses Cost of Goods and Service, Excluding Depreciation, Depletion, and Amortization Service and manufacturing costs Invoices for the cost of product sold and service rendered, excluding depreciation, depletion, and amortization. Invoices Received for Services and Manufacturing Costs Paid invoices Related Party Transaction, Purchases from Related Party Related party transaction The term of the master services agreement entered into by the entity, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Master Services Agreement, Term Master Services Agreement Subsequent Event [Table] Subsequent Event [Line Items]